SCHEMBL4982102

SCHEMBL4982102

CCN(C(=O)[CH]c1ccccc1)C(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.47
NPC1 O15118 1/20 0.47
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
PGR P06401 1/20 0.41
ADRA2A P08913 1/20 0.41
ADRA2B P18089 1/20 0.41
HTR2A P28223 1/20 0.41
HRH1 P35367 1/20 0.41
KCNH2 Q12809 1/20 0.41
HTT P42858 1/20 0.40
ALDH1A1 P00352 6/20 0.39
NAMPT P43490 1/20 0.39
LMNA P02545 1/20 0.39
LTB4R Q15722 1/20 0.38
LTB4R2 Q9NPC1 1/20 0.38
GLA P06280 1/20 0.38
TSHR P16473 1/20 0.38
HPGD P15428 2/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5010041 0.84 NPC1 (0.43) L3MBTL1NPC1MEN1KMT2APGR
SCHEMBL7220837 0.82 NPC1 (0.44) L3MBTL1NPC1MEN1KMT2AHTT
SCHEMBL7215103 0.78 L3MBTL1 (0.68) L3MBTL1NPC1MEN1KMT2AALDH1A1
SCHEMBL4986055 0.77 NPC1 (0.51) L3MBTL1NPC1MEN1KMT2AALDH1A1
SCHEMBL1004615 0.77 NAMPT (0.55) L3MBTL1MEN1KMT2APGRADRA2A
SCHEMBL5315363 0.74 PGR (0.50) L3MBTL1MEN1KMT2APGRADRA2A
SCHEMBL4986792 0.72 NPC1 (0.47) L3MBTL1NPC1MEN1KMT2AHTT
SCHEMBL25605899 0.72 MEN1 (0.53) NPC1MEN1KMT2AHTTALDH1A1
SCHEMBL3856122 0.71 TP53 (0.52) L3MBTL1NPC1MEN1KMT2AHTT
SCHEMBL5613928 0.71 NPC1 (0.44) L3MBTL1NPC1KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7393958-B2 Triamide-substituted heterobicyclic compounds PFIZER, INC. (US) 2008-07-01 US disclosed
US-7368573-B2 Triamide-substituted heterobicyclic compounds PFIZER INC. (US) 2008-05-06 US disclosed
US-20070093525-A1 Triamide-substituted heterobicyclic compounds PFIZER INC 2007-04-26 US disclosed
US-20060223851-A1 TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS BERTINATO PETER 2006-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223851-A1 TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS APOB, MTPN, CTRB1 L3MBTL1 1120/4885NPC1 32/4885MEN1 1637/4885
US-20070093525-A1 Triamide-substituted heterobicyclic compounds APOB, MTPN, CTRB1 L3MBTL1 1120/4885NPC1 32/4885MEN1 1637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.